Helena A Patsos
The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells
Patsos, Helena A; Greenhough, Alexander; Hicks, Diane J; Al Kharusi, Manal; Collard, Tracey J; Lane, Jon D; Paraskeva, Chris; Williams, Ann C
Authors
Alexander Greenhough Alexander.Greenhough@uwe.ac.uk
Associate Professor of Health Diagnostics
Diane J Hicks
Manal Al Kharusi
Tracey J Collard
Jon D Lane
Chris Paraskeva
Ann C Williams
Abstract
Despite recent advances in understanding colorectal tumour biology, there is still a need to improve the 5-year survival rate of patients with colorectal cancer as approximately 40% of patients presenting with advanced disease will remain resistant to therapy. One of the major contributing factors in resistance to therapy is the failure of colorectal tumour cells to undergo apoptosis. Hence there is an urgent need to develop novel therapeutic approaches that can target apoptosis-resistant cells. To this end, we investigated the potential efficacy of the endogenous cannabinoid anandamide to induce cell death in apoptosis-resistant colon cancer cells. Here, for the first time, we show that anandamide can induce cell death in the apoptosis-resistant HCT116 Bax -/-colorectal cell line. Importantly, we provide direct genetic evidence that this induction of cell death is dependent on COX-2 expression. Interestingly, increased COX-2 expression also sensitised the SW480 colorectal cancer cell line (low endogenous COX-2) to anandamide-induced death, whereas COX-2 suppression by RNAi inhibited anandamide-induced cell death in the HCA7 colorectal cancer cell line (high endogenous COX-2 expression). This COX-2-dependent death was independent of cannabinoid receptor engagement (CB1 or CB2), and not a direct consequence of reactive oxygen species (ROS) formation. This study demonstrates a novel utilisation for COX-2 expression, targeting apoptotic defective colorectal cancer cells for destruction by anandamide. As COX-2 is not expressed in the normal colorectal epithelium, but highly expressed in colorectal tumours and apoptosis resistance contributes to treatment failure, these data suggest that anandamide has the potential to be an effective therapeutic in colorectal cancer.
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 2, 2010 |
Online Publication Date | Jul 1, 2010 |
Publication Date | Jul 31, 2010 |
Journal | International Journal of Oncology |
Print ISSN | 1019-6439 |
Electronic ISSN | 1791-2423 |
Publisher | Spandidos Publications |
Peer Reviewed | Peer Reviewed |
Volume | 37 |
Issue | 1 |
Pages | 187-193 |
DOI | https://doi.org/10.3892/ijo_00000666 |
Public URL | https://uwe-repository.worktribe.com/output/976765 |
Publisher URL | https://doi.org/10.3892/ijo_00000666 |
You might also like
Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3
(2024)
Journal Article
BCL–3 promotes cyclooxygenase–2/prostaglandin E2 signalling in colorectal cancer
(2020)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search